OBJECTIVES: Malignant ascites (MA) caused by peritoneal carcinomatosis is not uncommon in patients with pancreatic cancer. However, the clinical features and outcomes in these patients remain to be elucidated. METHODS: Baseline characteristics and overall survival (OS) of consecutive patients with advanced pancreatic cancer who presented with MA were retrospectively evaluated. RESULTS: Of 494 patients with advanced pancreatic cancer, 73 (15%) presented with MA. Patients with synchronous MA (n = 21), compared with those with metachronous MA (n = 52), had better performance status (P = 0.02), smaller amount of ascites (P < 0.01), and higher chance of receiving chemotherapy (57% vs 17%, P < 0.01), and resulted in longer OS (115 vs 42 days, P < 0.01). Overall survival was significantly longer in patients receiving chemotherapy than in those with best supportive care alone (124 vs 50 days, P < 0.01). In a multivariate analysis, chemotherapy was prognostic in addition to performance status, CRP, and small amount of MA; the hazard ratio of chemotherapy was 0.46, compared with best supportive care alone (P = 0.02). CONCLUSIONS: Although the prognosis of pancreatic cancer patients with MA remains poor, selected patients may be candidate for chemotherapy, regardless of the timing of appearance of MA.
OBJECTIVES:Malignant ascites (MA) caused by peritoneal carcinomatosis is not uncommon in patients with pancreatic cancer. However, the clinical features and outcomes in these patients remain to be elucidated. METHODS: Baseline characteristics and overall survival (OS) of consecutive patients with advanced pancreatic cancer who presented with MA were retrospectively evaluated. RESULTS: Of 494 patients with advanced pancreatic cancer, 73 (15%) presented with MA. Patients with synchronous MA (n = 21), compared with those with metachronous MA (n = 52), had better performance status (P = 0.02), smaller amount of ascites (P < 0.01), and higher chance of receiving chemotherapy (57% vs 17%, P < 0.01), and resulted in longer OS (115 vs 42 days, P < 0.01). Overall survival was significantly longer in patients receiving chemotherapy than in those with best supportive care alone (124 vs 50 days, P < 0.01). In a multivariate analysis, chemotherapy was prognostic in addition to performance status, CRP, and small amount of MA; the hazard ratio of chemotherapy was 0.46, compared with best supportive care alone (P = 0.02). CONCLUSIONS: Although the prognosis of pancreatic cancerpatients with MA remains poor, selected patients may be candidate for chemotherapy, regardless of the timing of appearance of MA.
Authors: Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim Journal: Clin Exp Metastasis Date: 2021-01-24 Impact factor: 5.150
Authors: E Bonnet; C Mastier; A Lardy-Cléaud; P Rochefort; M Sarabi; P Guibert; A Cattey-Javouhey; F Desseigne; C de La Fouchardière Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Marina Baretti; Bhargavi Pulluri; Hua-Ling Tsai; Amanda L Blackford; Christopher L Wolfgang; Daniel Laheru; Lei Zheng; Joseph Herman; Dung T Le; Amol K Narang; Ana de Jesus-Acosta Journal: Pancreas Date: 2019-04 Impact factor: 3.243
Authors: Stacey M Stein; Edward S James; Yanhong Deng; Xiangyu Cong; Jeremy S Kortmansky; Jia Li; Carol Staugaard; Doddamane Indukala; Ann Marie Boustani; Vatsal Patel; Charles H Cha; Ronald R Salem; Bryan Chang; Howard S Hochster; Jill Lacy Journal: Br J Cancer Date: 2016-03-29 Impact factor: 7.640